INDISCRIMINATE USE OF GLP-1 ANALOGUES, SUCH AS SEMAGLUTIDE (OZEMPIC®), FOR AESTHETIC PURPOSES AND MULTIDISCIPLINARY ACTION IN CARE AND RISK PREVENTION. Editora Impacto Científico, [S. l.], p. 342–356, 2025. Disponível em: https://periodicos.newsciencepubl.com/editoraimpacto/article/view/9073. Acesso em: 20 feb. 2026.